Filing Details

Accession Number:
0001104659-21-003111
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-11 19:54:53
Reporting Period:
2021-01-07
Accepted Time:
2021-01-11 19:54:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1744659 Akero Therapeutics Inc. AKRO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1779805 Jonathan Young C/o Akero Therapeutics, Inc.
601 Gateway Boulevard, Suite 350
South San Francisco CA 94080
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-07 7,500 $0.62 189,285 No 4 M Direct
Common Stock Disposition 2021-01-08 10,000 $28.12 179,285 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-01-07 7,500 $0.00 7,500 $0.62
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,296 2028-07-29 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 20,000 Indirect By EA Irrevocable Trust
Common Stock 20,000 Indirect By CM Irrevocable Trust
Common Stock 20,000 Indirect By JL Irrevocable Trust
Footnotes
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  4. 25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.